GeneralNews

FDA Approves Bayer's Macrocyclic GBCA Gadoquatrane (AMBELVIST)

The Imaging WireJun 30

FDA approved Bayer's macrocyclic gadolinium-based contrast agent AMBELVIST (gadoquatrane), offering a new option for contrast-enhanced MRI across clinical settings.

  • Gadoquatrane is a high-relaxivity macrocyclic GBCA designed for improved stability.
  • Bayer positions the approval as strengthening its connected MR portfolio to support imaging programs.
  • No specific diagnostic performance or safety statistics were provided in the trade press announcement.
Read the source

Also covered by

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.